Scientists test high doses of antiviral drug in healthy people

NCT ID NCT06024421

Summary

This early-stage study aims to test the safety of giving high doses of the antiviral drug favipiravir to healthy volunteers for 14 days. Researchers will closely monitor participants for side effects and measure how the drug moves through and is processed by the body, including its levels in blood and sperm. The goal is to gather essential safety and processing data to inform future research, not to treat an active infection.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFECTIOUS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University Hospital Bichat - Claude Bernard

    RECRUITING

    Paris, 75018, France

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.